- Home
- BHE vs AUPH Comparison
BHE vs AUPH Comparison
Compare BHE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHE | AUPH |
|---|---|---|
| Founded | 1979 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BHE | AUPH |
|---|---|---|
| Price | $74.00 | $16.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $55.00 | $17.25 |
| AVG Volume (30 Days) | 280.2K | ★ 920.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | ★ 0.91 | 0.53 |
| Revenue | ★ $2,659,108,000.00 | $283,055,000.00 |
| Revenue This Year | $7.03 | $17.54 |
| Revenue Next Year | $6.57 | $15.74 |
| P/E Ratio | $81.23 | ★ $30.32 |
| Revenue Growth | 0.11 | ★ 20.38 |
| 52 Week Low | $35.97 | $10.34 |
| 52 Week High | $100.41 | $19.25 |
Technical Indicators
Market Signals| Indicator | BHE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 53.46 |
| Support Level | $72.31 | $14.61 |
| Resistance Level | $86.86 | $16.46 |
| Average True Range (ATR) | 2.02 | 0.44 |
| MACD | 0.39 | -0.03 |
| Stochastic Oscillator | 87.18 | 20.51 |
Price Performance
Historical ComparisonAbout BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.